However, anti-VEGF treatment in the prevention of microvascular disease is associated with serious obstacles, since, for example, VEGF165 antibodies cause renal damage and hypertension in lung cancer patients, and nephrotoxicity commonly occurs after anti-VEGF therapy as previously reviewed [19,20]. This evidence concerns the gene VEGFA and lung cancer.